Real-life experiences with galcanezumab and predictors for treatment response in Turkey

Sadeleştirilmiş öğe sayfası
dc.contributor.authorYalinay Dikmen, Pinar
dc.contributor.authorBaykan, Betuel
dc.contributor.authorUluduz, Derya
dc.contributor.authorOzge, Aynur
dc.contributor.authorIlgaz Aydinlar, Elif
dc.contributor.authorPolat, Burcu
dc.contributor.authorKarli, Necdet
dc.contributor.authorTepe, Nermin
dc.contributor.authorCelebisoy, Nese
dc.contributor.authorErgin Toktas, Hayal
dc.contributor.authorNiflioglu, Buket
dc.contributor.authorKaraci, Rahsan
dc.contributor.authorMayda Domac, Fusun
dc.contributor.authorUluduz, Ezgi
dc.contributor.authorErdogan Soyukibar, Tuba
dc.contributor.authorOksuez, Nevra
dc.contributor.authorErtas, Mustafa
dc.date.accessioned2025-10-16T15:14:12Z
dc.date.issued2023
dc.identifier.doi10.1186/s12883-023-03467-1
dc.identifier.otherWOS:001107771300001
dc.identifier.urihttps://openaccess.acibadem.edu.tr/handle/11443/6093
dc.publisherBMC
dc.sourceBMC NEUROLOGY
dc.subjectCalcitonin gene\\-related peptide
dc.subjectCGRP
dc.subjectGalcanezumab
dc.subjectmAbs
dc.subjectMonoclonal antibody
dc.subjectMigraine
dc.subjectMigraine prevention
dc.subjectAnti\\-CGRP
dc.titleReal-life experiences with galcanezumab and predictors for treatment response in Turkey
dc.typeArticle

Dosyalar

Koleksiyonlar

WOS